Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
66 results about "Cholangeitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sulfonyl urea derivatives and their use in control of interleukin-1 activity
A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and / or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.
Owner:PFIZER INC
Traditional Chinese medicine composition for treating autoimmune liver disease and preparation method thereof
InactiveCN103356956AImprove the effectCompatibility is reasonableDigestive systemImmunological disordersRemove bloodSurvival quality
The invention discloses a traditional Chinese medicine composition for treating an autoimmune liver disease, and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-30 parts of cooked rhubarb, 10-30 parts of glossy privet fruit, 10-30 parts of radix curcumae, 10-30 parts of large-leaved gentian, 10-30 parts of caulis spatholobi, 10-30 parts of caulis sinomenii, 10-30 parts of radix rubiae, 10-30 parts of sedum sarmentosum and 5-15 parts of liquorice. The traditional Chinese medicine has the effects of strengthening body resistance, detoxifying, dispersing stagnated liver qi for promoting bile flow, promoting blood circulation to remove blood stasis, expelling wind and removing dampness; the main treatment range comprises autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and overlap syndrome of any two in the three diseases; and the traditional Chinese medicine composition has the treatment effects of restoring immune balance, inhibiting liver inflammation, protecting liver function, resisting hepatic fibrosis, improving clinical symptoms, improving survival quality and the like, and has high safety.
Owner:毛德文 +1
Pharmaceutical compositions for combination therapy
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.
Owner:INTERCEPT PHARMA INC
Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof
The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Suspension powder injection of cefamandole nafate and new application thereof
InactiveCN101637456AEasy to storeEasy to transportAntibacterial agentsPowder deliverySuppurative cholangitisSURFACTANT BLEND
The invention relates to suspension powder injection of cefamandole nafate and a preparation method thereof and further relates to new application of the injection in treating acute suppurative cholangitis. The frozen-dried suspension powder injection comprises the following components in parts by weight: 1 part of cefamandole nafate, 1.5-12 parts of surfactant and 2-15 parts of frozen-dried supporting agents.
Owner:HAINAN YONGTIAN PHARMA INST
Methods and Compositions for Diagnosis of Inflammatory Liver Disease
ActiveUS20150219664A1Easy diagnosisGood differential diagnosisOrganic active ingredientsHealth-index calculationPrimary biliary cirrhosisLiver disease
The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and / or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER +1
Cefetamet pivoxil hydrochloride submicron emulsion solid preparation and new application thereof
InactiveCN101721371AImprove stabilityImprove solubilityAntibacterial agentsPowder deliveryEmulsionAdhesive
The invention provides a cefetamet pivoxil hydrochloride submicron emulsion solid preparation, which comprises the following components in part by weight: 1 part of cefetamet pivoxil hydrochloride submicron emulsion grains, 0.4 to 3 parts of diluent, 0 to 0.5 part of disintegrating agent, 0 to 0.2 part of adhesive, 0 to 6 parts of flavoring agent, 0 to 0.4 part of aromatizer and 0 to 0.2 part of lubricant. The invention also discloses application of the preparation in preparation of a medicament for treating cholangitis, particularly acute pyogenic cholangitis.
Owner:HAINAN MEIDA PHARMA
Compounds and methods for treatment of primary biliary cholangitis
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and / or vitamin D supplement, and vitamin A, D, E and / or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).
Owner:ARENA PHARMA
Non human animal model for ulcerative colitis and its main complications
InactiveUS20140373186A1Compounds screening/testingMicrobiological testing/measurementTargeted disruptionHuman animal
The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Medical application of encoding gene ESRRA of estrogen-related receptor alpha (ERR alpha)
PendingCN113117097AEasily damagedReduce lipid accumulationPeptide/protein ingredientsDigestive systemAdenoassociated virusBile Juice
The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.
Owner:CHINA PHARM UNIV
Application of prevotella in preparation of medicine for treating cholestatic diseases
PendingCN113509494AReduce sedimentationImprove fibrosisBacteria material medical ingredientsDigestive systemEnterohepatic circulationBile Juice
The invention discloses application of prevotella in preparation of a medicine for treating cholestatic diseases. The cholestatic diseases include, but is not limited to, primary sclerosing cholangitis. After the inventor constructs a PSC animal model, it is determined that the abundance of P.copri in mice is consistently reduced in the same population, then intervention effects of P.copri on inflammation, fibrosis, cholestasis and the like of the PSC model are observed and evaluated through intragastric administration for one week and daily supplementation of 1*10<8> CFU of P.copri bacterial liquid, bile acid metabolism changes are determined through total bile acid determination and targeted bile acid detection analysis, and the action mechanism is analyzed. Experiments prove that the P.copri can obviously relieve cholestasis in hepatointestinal circulation of PSC mice and obviously improve liver fibrosis, which is of great significance to prevention or treatment of cholestatic diseases.
Owner:NANJING MEDICAL UNIV
Compositions and methods for treating neonatal biliary atresia
Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Unilateral-wing bile-duct inner stent with stent-withdrawing line
The invention relates to the technical field of medical equipment, in particular to a unilateral-wing bile-duct inner stent with a stent-withdrawing line. The unilateral-wing bile-duct comprises a tubular stent (1), a lateral wing (2) and the withdrawing line. The lateral-wing (2) is located at a near end of the stent (1). The withdrawing line is composed of a line (3) and a withdrawing rod (4), one end of the line (3) is tied to the middle of the withdrawing rod (4), while the other end of the same is fixed onto a far end of the stent (1). The unilateral-wing bile-duct stent is simple in structure and convenient to use, so that withdrawing or replacing the stent is facilitated. The line of the drawing line is thin, so that a barrier function of the duodenal papilla cannot be affected, intestinal bacteria can be prevented from retrograding to enter the bile duct to cause cholangitis, the intestinal bacterial can also be prevented from attaching to an inner wall of the stent or blocking the stent due to food reflux, and bleeding, perforating and retrograde bile-duct infection and the like caused by the fact that the duodenal papilla is needed to be cut open since the stent fails to be withdrawn are avoided.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Methods of Treating Ascites
The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg / day and / or spironolactone >100 mg / day or equivalent doses of an alternative loop-acting and / or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.
Owner:MACALLISTER THOMAS W +1
Pyrrolidine derivatives as PPAR agonists
The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
Owner:GUANGDONG RAYNOVENT BIOTECH CO LTD
Traditional Chinese medicine combination for treating hepatobiliary diseases and preparation method thereof
InactiveCN107397776AHas an immunomodulatory effectRegulate hormonesOrganic active ingredientsDigestive systemHepatobiliary diseaseGanoderma lucidum
The invention discloses a traditional Chinese medicine combination for treating hepatobiliary diseases and a preparation method thereof. The traditional Chinese medicine combination is composed of the following raw materials, by weight, of 200-300 parts of ganoderma lucidum soak solutions, 30-60 parts of antrodia camphorata polysaccharide, 70-100 parts of selenium-enriched pleurotus ostreatus fruiting body powder, 10-20 parts of bear bile powder, 100-200 parts of panax notoginseng powder, 80-120 parts of rock candies and 180-220 parts of tilia honey. The traditional Chinese medicine combination has good curative effect on treating liver cirrhosis, viral hepatitis type B, cholangitis, gallstones, a bile duct cancer and a gallbladder cancer.
Owner:林树芳
Molecular marker for diagnosing primary biliary cholangitis and application thereof
PendingCN114088939AImprove the level ofTraumaDisease diagnosisBiological testingBile fluidAntibody level
The invention discloses a molecular marker for diagnosing primary biliary cholangitis and application thereof. According to the present invention, the anti-human multimer immunoglobulin receptor antibody is adopted as the primary biliary cholangitis diagnosis molecular marker so as to prepare the diagnosis reagent; the human multimer immunoglobulin receptor antibody is remarkably increased in serum of PBC AMA-M2 subtype positive and negative patients, which indicates that in the attack of PBC, the serum anti-human multimer immunoglobulin receptor antibody specifically targets human multimer immunoglobulin receptors on small and medium bile ducts in the liver, thereby causing damage to the small and medium bile ducts. According to the invention, a new explanation is provided for the pathogenesis of the PBC, and in addition, a new means is provided for the specific diagnosis of the PBC by detecting the level of the serum anti-human multimeric immune globulin receptor antibody. The method is simple and reliable, materials are convenient to obtain, and the method has great application value in PBC diagnosis.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV +1
Fluorinated bile acid derivatives
ActiveCN112771063AHas FXR agonist activityIncrease valueSulfonylurea active ingredientsDigestive systemBile JuiceBiliary tract
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis.
Owner:NZP UK LTD +1
Chinese medicinal preparation for treating cholecystitis and cholangitis
The invention provides a Chinese medicine preparation for treating cholecystitis and cholangitis. The preparation comprises, by weight, 100-200 parts of mung bean soaking in fresh cattle bile, 50-60 parts of radices saussureae, 20-30 parts of scutellaria baicalensism, 25-30 parts of cape jasmine, 20-30 parts of stigmata maydis, 20-25 parts of serrate rabdosia herb, 15-20 parts of artemisiacapillarisThunb, 20-30 parts of common andrographis, 20-25 parts of desmodium, 15-20 parts of medicated leaven, 15-20 parts of ventriculi galli mucosa, 15-20 parts licorice, and 15-20 parts of radix gentianae. The preparation can be used for treating cholecystitis and cholangitis with the effectiveness higher than 80%.
Owner:赵海苹
Application and application of reagents for detecting serum exosome pigr in the preparation of kits for diagnosing primary biliary cholangitis and predicting its curative effect
The invention belongs to the field of medical detection, and relates to a serum exosome PIGR, specifically to a use for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitisand predicting curative effect. The technical solution adopted by the invention is a kit for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitis and predicting curative effect, which is characterized by including the following components: a pIgR standard, a polystyrene ELISA (Enzyme Linked Immunosorbent Assay) microplate coated with pIgR antigens, a second enzyme-labeled antibody, a sample diluent, and an auxiliary reagent. The technical solution of the application method of the kit includes the following steps of: (1) preparing the sample diluent; (2) diluting thepIgR standard with a BSA-PBS solution into 8 gradients; (3) adding the standard and the sample diluent to a microplate; (4) adding the second enzyme-labeled antibody to each well; (5) adding a color developing liquid to each well; and (6) using a microplate reader to read an OD value at a wavelength of 450 nm , drawing a standard curve, and converting pIgR concentration in the sample. New kits andapplications are implemented by employing the above schemes.
Owner:THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Method for treating primary sclerosing cholangitis
The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.
Owner:アヴォリント
Composition for treating hepatitis-cholangitis overlap syndrome by using Yunnan paris polyphylla as main raw material as well as preparation method, preparation and application of composition
The invention discloses a composition for treating hepatitis-cholangitis overlap syndrome by using Yunnan paris polyphylla as a main raw material as well as a preparation method, a preparation and application of the composition. The composition for treating the hepatitis-cholangitis overlap syndrome by taking the Yunnan rhizoma paridis as the main raw material is prepared from the following raw materials in parts by weight: 1000 to 2500 parts of herba artemisiae scopariae, 500 to 1500 parts of rhizoma paridis, 1000 to 3000 parts of radix paeoniae rubra, 300 to 1500 parts of scorpio, 1000 to 2000 parts of pericarpium citri reticulatae viride, 1000 to 2000 parts of radix aucklandiae, 1000 to 3000 parts of rhizoma smilacis glabrae, 1000 to 2500 parts of cortex dictamni, 1000 to 3000 parts of malt and 500 to 1500 parts of liquorice root. The preparation can be granules, tablets, capsules, oral solutions and syrups. The application refers to the application of the composition for treating the hepatitis-cholangitis overlap syndrome by taking the Yunnan paris polyphylla as the main raw material in preparing a medicine for treating the hepatitis-cholangitis overlap syndrome.
Owner:YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
PendingCN113348178AEliminate or reduce riskSmall doseDigestive systemImmunoglobulins against cytokines/lymphokines/interferonsAntiendomysial antibodiesBile Juice
Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies.
Owner:MAPLE BIOTECH LLC
Biomarker for diagnosing primary sicca syndrome and application of biomarker
The invention relates to a biomarker for diagnosing primary sicca syndrome and application of the biomarker. According to the biomarker for diagnosing primary sicca syndrome and application of the biomarker of the invention, a lectin microarray containing 56 types of lectins is adopted to detect a glycan spectrum of specific binding of the serum IgG and the lectin of a patient with the primary sicca syndrome (PSS). The results show that LCA lectin binding glycan content is increased in the patient with primary biliary cholangitis (PBC) compared with that of a healthy person. As the LCA lectin is specific binding fucose, the expression of the fucose level in the patient withPSS is increased. A lectin immunoblotting verification result shows that the content of the LCA lectin binding glycan is still increased in the patient with the PSS. Therefore, the LCA lectin binding glycan level in the serum IgG can be used as a marker of the primary sicca syndrome (PSS).
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Use of sglt2 inhibitors to treat primary sclerosing cholangitis
PendingUS20210393662A1Improve and maintain clinical outcomeOrganic active ingredientsDispersion deliveryOncologyCancer research
The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.
Owner:AVOLYNT
Application of polypeptide AT03 in medicine used for treating primary biliary cholangitis
PendingCN112656934AImprove biological activityStrong medicinal effectAntipyreticDigestive systemBiliary obstructionsBiliary tract
The invention discloses application of polypeptide AT03 in a medicine used for treating primary biliary cholangitis. The amino acid sequence of the polypeptide AT03 is Val-His-Val-Val-R1, wherein R1 is -NH2. A large number of experimental studies prove that the polypeptide AT03 has a treatment effect on a common bile duct-ligated rat cholestatic liver cirrhosis model, and the treatment effect is specifically shown in that liver cholestasis, intrahepatic biliary obstruction, liver cell injury and liver tissue fibrosis process can be improved; and the polypeptide AT03 can be used for preparing the medicine used for treating primary biliary cholangitis.
Owner:SHENZHEN TURIER BIOTECH CO LTD
Pyrrolidine derivatives as PPAR agonists
ActiveUS20190225597A1High activityHigh selectivityOrganic chemistryMetabolism disorderDyslipidemiaTG - Triglyceride
The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
Owner:GUANGDONG RAYNOVENT BIOTECH CO LTD
Sickle Cell Disease Treatment Utilizing Omega-3 Fatty Acids
ActiveUS20200093779A1Increase surface areaImprove bioavailabilityHydroxy compound active ingredientsPharmaceutical non-active ingredientsActive agentIngested food
Owner:GENERX INC
Endobiliary drainage tube for preventing duodenal papilla bleeding
The invention provides an endobiliary drainage tube for preventing duodenal papilla bleeding. The endobiliary drainage tube comprises a drainage tube body, an inner core and a propeller, wherein at least two side holes are formed in the head tube section of the drainage tube body, a cylindrical balloon is attached to the middle tube section of the drainage tube body, a one-way injection valve is arranged in the tail tube section of the drainage tube body, and the head of the injection valve is communicated with the balloon; the balloon is cylindrical after being filled; the head of the inner core comprises a channel I and a needle tube, the channel I is arranged in a tube cavity of the drainage tube body and penetrates out, and the needle tube penetrates through the tail end of the injection valve; the tail part of the inner core is positioned in a pipe cavity of the propeller; the tail part comprises a channel II communicated with the channel I and a channel III communicated with theneedle tube; a channel IV communicated with the channel II and a channel V communicated with the channel III are arranged in the base of the inner core; and the channel V is connected with a balloon injection joint. While bile is drained, the filled balloon can press the duodenal papilla sphincter, and postoperative cholangitis and duodenal papilla bleeding can be prevented.
Owner:SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com